Metabiota Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 84

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 2

Metabiota General Information

Description

Developer of risk analytic software designed to assess and respond to infectious disease threats through pathogen discovery. The company's platform allows local authorities to prepare mitigation strategies by conducting disease detection and threat characterization research to accurately quantify complex infectious disease risks, enabling governments and corporations to manage and mitigate infectious diseases.

Contact Information

Formerly Known As
Epintel, Global Viral Forecasting
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Media and Information Services (B2B)
Other Industries
Business/Productivity Software
Parent Company
Heada
Corporate Office
  • 2443 Fillmore
  • Suite 380-5027
  • San Francisco, CA 94115
  • United States
+1 (415) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Metabiota Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 14-Oct-2022 Completed Generating Revenue
15. Grant 31-Dec-2021 00.000 Completed Generating Revenue
14. Merger/Acquisition 30-Sep-2021 000.00 Completed Generating Revenue
13. Debt - PPP 02-Feb-2021 00000 000.00 Completed Generating Revenue
12. Grant 31-Dec-2020 00.00 000.00 Completed Generating Revenue
11. Debt - PPP 15-Apr-2020 00000 000.00 Completed Generating Revenue
10. Grant 31-Dec-2019 00.000 000.00 Completed Generating Revenue
9. Grant 31-Dec-2018 00.000 000.00 Completed Generating Revenue
8. Later Stage VC (Series B) 09-Nov-2018 $7.5M $57.5M 00000 Completed Generating Revenue
7. Grant 31-Dec-2017 $1.86M $50M Completed Generating Revenue
To view Metabiota’s complete valuation and funding history, request access »

Metabiota Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.00 00.00 00.00 00.00 00.000
Series A 00,000,000 00.00 00.00 00.00 00 00.00 00.000
Seed 7,591,990 $0.03 $0.38 $0.38 1x $0.38 9.41%
To view Metabiota’s complete cap table history, request access »

Metabiota Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of risk analytic software designed to assess and respond to infectious disease threats through pathogen discov
Media and Information Services (B2B)
San Francisco, CA
84 As of 2022
000.00
000000&0

000000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
00000 000 0000000000
New York, NY
00 As of 0000
000.00
000 0000-00-00
000000&0 000.00

000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolor
00000 000 0000000000
Toronto, Canada
000 As of 0000
000.00
0000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Metabiota Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Predata Formerly VC-backed New York, NY 00 000.00 000000&0 000.00
BlueDot (Media and Information Services) Venture Capital-Backed Toronto, Canada 000 000.00 0000 000.00
CXA Group Venture Capital-Backed Singapore, Singapore 00 00000 00000000000 00000
Firstbeat Venture Capital-Backed Jyvaskyla, Finland 000 0000 0000000000 0 0000
Tellius Venture Capital-Backed Reston, VA 00 0000 00000000000 0000
You’re viewing 5 of 7 competitors. Get the full list »

Metabiota Patents

Metabiota Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190370834-A1 System for determining public sentiment towards pathogens Inactive 01-Jun-2018 00000000000 0
EP-3576101-A1 A system for determining public sentiment towards pathogens Inactive 01-Jun-2018 00000000000 0

Metabiota Executive Team (18)

Name Title Board Seat Contact Info
Nita Madhav Chief Executive Officer
Chris DiBona Advisor
Zachary Bogue JD Advisor
You’re viewing 3 of 18 executive team members. Get the full list »

Metabiota Board Members (11)

Name Representing Role Since
Ryan Phillips WP Global Partners Board Observer 000 0000
You’re viewing 1 of 11 board members. Get the full list »

Metabiota Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Metabiota Former Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adrian Aoun Angel (individual) Minority 000 0000 000000 0
Baktus Corporation Majority 000 0000 000000 0
Capricorn Investment Group Impact Investing Minority 000 0000 000000 0
DCVC Venture Capital Minority 000 0000 000000 0
Falkon Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 25 investors. Get the full list »

Metabiota Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ancera 28-Jun-2016 00000 0000 000.00 Business/Productivity Software 000000 00
To view Metabiota’s complete investments history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »